Workflow
头孢粉针剂
icon
Search documents
东瑞制葯公布中期业绩 母公司拥有人应占溢利约1.05亿元 同比减少78.79%
Zhi Tong Cai Jing· 2025-08-22 15:03
Core Viewpoint - Dongrui Pharmaceutical (02348) reported a mid-year performance for 2025, showing a revenue of approximately 630 million, a year-on-year increase of 9.2%, but a significant decline in net profit attributable to shareholders by 78.79% [1] Financial Performance - Revenue reached approximately 630 million, reflecting a year-on-year growth of 9.2% [1] - Gross profit was about 314 million, representing a year-on-year decrease of 7.1% [1] - Net profit attributable to shareholders was approximately 105 million, down 78.79% year-on-year [1] - Earnings per share stood at 0.06961, with an interim dividend of 0.015 HKD per share [1] Product Performance - Sales volume of the hypertension treatment "An" series decreased by 5.7%, with sales revenue declining by 22.1%, primarily due to price reductions in certain regions influenced by national procurement policies [1] - Sales volume of the antiviral drug Entecavir dispersible tablets increased by 14.0%, with sales revenue growing by 8.7% [1] - The product series focused on treating hyperlipidemia in Fujian saw a sales volume increase of 19.5% and sales revenue growth of 16.6% [1] - Sales volume of cephalosporin powder injection grew by 47.9%, with sales revenue increasing by 55.7% [1] - Sales volume of intermediates and raw materials increased by 244.8%, with sales revenue rising by 142.7%, attributed to the commercialization of the Suzhou Dongrui and Lanzhou Dongrui facilities [1] Challenges - The decline in profit was mainly due to the lack of large-scale commercial production at the Suzhou Dongrui and Lanzhou Dongrui facilities, price reductions of the "An" series products in certain provinces due to national policies, and increased R&D expenses [1]
东瑞制葯(02348)公布中期业绩 母公司拥有人应占溢利约1.05亿元 同比减少78.79%
智通财经网· 2025-08-22 14:56
Core Insights - Dongrui Pharmaceutical (02348) reported a mid-year performance for 2025, with revenue of approximately 630 million, representing a year-on-year increase of 9.2% [1] - Gross profit was approximately 314 million, showing a year-on-year decrease of 7.1% [1] - Profit attributable to the parent company was approximately 105 million, a significant year-on-year decrease of 78.79% [1] - Earnings per share were 0.06961, with an interim dividend of 0.015 HKD per share [1] Revenue Breakdown - Sales volume of the hypertension treatment "An" series decreased by 5.7%, with sales revenue declining by 22.1%, primarily due to price reductions in certain regions influenced by national procurement policies [1] - Sales volume of the antiviral drug Entecavir dispersible tablets increased by 14.0%, with sales revenue growing by 8.7% [1] - The product series focused on treating hyperlipidemia in Fujian saw a sales volume increase of 19.5% and a sales revenue increase of 16.6% [1] - Sales volume of cephalosporin powder injection increased by 47.9%, with sales revenue rising by 55.7% [1] Production and Operational Insights - With the commercial production of the Suzhou Dongrui Pharmaceutical Co., Ltd. and Lanzhou Dongrui Pharmaceutical Co., Ltd. facilities, the sales volume of intermediates and raw materials increased by 244.8%, and sales revenue grew by 142.7% compared to the same period in 2024 [1] - The decline in profit during this period was attributed to the lack of large-scale commercial production at the Suzhou and Lanzhou facilities, price reductions of "An" series products due to national policies in certain provinces, and increased R&D expenses [1]